{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:30:42Z","timestamp":1792812642727,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21874142"],"award-info":[{"award-number":["21874142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21635008"],"award-info":[{"award-number":["21635008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Key R&D Program of China","award":["2018YFA0800900"],"award-info":[{"award-number":["2018YFA0800900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cisplatin, the alkylating agent of platinum(II) (Pt(II)), is the most common antitumor drug in clinic; however, it has many side effects, therefore it is higly desired to develop low toxicity platinum(IV) (Pt(IV)) drugs. Multi-omics analysis, as a powerful tool, has been frequently employed for the mechanism study of a certain therapy at the molecular level, which might be helpful for elucidating the mechanism of platinum drugs and facilitating their clinical application.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Strating form cisplatin, a hydrophobic Pt(IV) prodrug (CisPt(IV)) with two hydrophobic aliphatic chains was synthesized, and further encapsulated with a drug carrier, human serum albumin (HSA), to form nanoparticles, namely AbPlatin<jats:sup>(IV)<\/jats:sup>. The anticancer effect of AbPlatin<jats:sup>(IV)<\/jats:sup> was investigated in vitro and in vivo. Moreover, transcriptomics, metabolomics and lipidomics were performed to explore the mechanism of AbPlatin(IV).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with cisplatin, Abplatin<jats:sup>(IV)<\/jats:sup> exhibited better tumor-targeting effect and greater tumor inhibition rate. Lipidomics study showed that Abplatin<jats:sup>(IV)<\/jats:sup> might induce the changes of BEL-7404 cell membrane, and cause the disorder of glycerophospholipids and sphingolipids. In addition, transcriptomics and metabolomics study showed that Abplatin<jats:sup>(IV)<\/jats:sup> significantly disturbed the purine metabolism pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This research highlighted the development of Abplatin<jats:sup>(IV)<\/jats:sup> and the use of multi-omics for the mechanism elucidation of prodrug, which is the key to the clinical translation of prodrug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12951-022-01465-y","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:03:45Z","timestamp":1654250625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Abplatin(IV) inhibited tumor growth on a patient derived cancer model of hepatocellular carcinoma and its comparative multi-omics study with cisplatin"],"prefix":"10.1186","volume":"20","author":[{"given":"Xing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingpu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1021\/acs.chemrestox.9b00204","volume":"32","author":"L Qi","year":"2019","unstructured":"Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32:1469\u201386.","journal-title":"Chem Res Toxicol"},{"key":"1465_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/222385a0","volume":"222","author":"B Rosenberg","year":"1969","unstructured":"Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385\u20136.","journal-title":"Nature"},{"key":"1465_CR3","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1021\/cr980420v","volume":"99","author":"E Wong","year":"1999","unstructured":"Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev. 1999;99:2451\u201366.","journal-title":"Chem Rev"},{"key":"1465_CR4","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/C8DT00838H","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47:6645\u201353.","journal-title":"Dalton Trans"},{"key":"1465_CR5","doi-asserted-by":"publisher","first-page":"8614","DOI":"10.1021\/ja028477t","volume":"125","author":"MP Jensen","year":"2003","unstructured":"Jensen MP, Wick DD, Reinartz S, White PS, Templeton JL, Goldberg KI. Reductive elimination\/oxidative addition of carbon-hydrogen bonds at Pt(IV)\/Pt(II) centers: mechanistic studies of the solution thermolyses of Tp(Me2)Pt(CH3)2H. J Am Chem Soc. 2003;125:8614\u201324.","journal-title":"J Am Chem Soc"},{"key":"1465_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1039\/B707077M","volume":"38","author":"CG Hartinger","year":"2009","unstructured":"Hartinger CG, Dyson PJ. Bioorganometallic chemistry\u2013from teaching paradigms to medicinal applications. Chem Soc Rev. 2009;38:391\u2013401.","journal-title":"Chem Soc Rev"},{"key":"1465_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.trechm.2021.03.006","volume":"3","author":"J Karges","year":"2021","unstructured":"Karges J, Stokes RW, Cohen SM. Metal complexes for therapeutic applications. Trends Chem. 2021;3:523\u201334.","journal-title":"Trends Chem"},{"key":"1465_CR8","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.1039\/C6DT01414C","volume":"45","author":"D Gibson","year":"2016","unstructured":"Gibson D. Platinum(iv) anticancer prodrugs\u2014hypotheses and facts. Dalton Trans. 2016;45:12983\u201391.","journal-title":"Dalton Trans"},{"key":"1465_CR9","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1039\/C6DT01562J","volume":"45","author":"Q Wang","year":"2016","unstructured":"Wang Q, Huang Z, Ma J, Lu X, Zhang L, Wang X, George Wang P. Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents. Dalton Trans. 2016;45:10366\u201374.","journal-title":"Dalton Trans"},{"key":"1465_CR10","doi-asserted-by":"publisher","first-page":"11830","DOI":"10.1039\/C6DT02207C","volume":"45","author":"J Ma","year":"2016","unstructured":"Ma J, Wang Q, Yang X, Hao W, Huang Z, Zhang J, Wang X, Wang PG. Glycosylated platinum(iv) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects. Dalton Trans. 2016;45:11830\u20138.","journal-title":"Dalton Trans"},{"key":"1465_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/cmdc.201402353","volume":"10","author":"W Neumann","year":"2015","unstructured":"Neumann W, Crews BC, Sarosi MB, Daniel CM, Ghebreselasie K, Scholz MS, Marnett LJ, Hey-Hawkins E. Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. ChemMedChem. 2015;10:183\u201392.","journal-title":"ChemMedChem"},{"key":"1465_CR12","doi-asserted-by":"publisher","first-page":"14174","DOI":"10.1039\/C7DT02928D","volume":"46","author":"E Gabano","year":"2017","unstructured":"Gabano E, Ravera M, Zanellato I, Tinello S, Gallina A, Rangone B, Gandin V, Marzano C, Bottone MG, Osella D. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. Dalton Trans. 2017;46:14174\u201385.","journal-title":"Dalton Trans"},{"key":"1465_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/1061186X.2017.1365878","volume":"25","author":"H Maeda","year":"2017","unstructured":"Maeda H. Polymer therapeutics and the EPR effect. J Drug Target. 2017;25:781\u20135.","journal-title":"J Drug Target"},{"issue":"567","key":"1465_CR14","first-page":"1","volume":"11","author":"X Zeng","year":"2020","unstructured":"Zeng X, Sun J, Li S, Shi J, Gao H, Sun Leong W, Wu Y, Li M, Liu C, Li P, et al. Blood-triggered generation of platinum nanoparticle functions as an anti-cancer agent. Nat Commun. 2020;11(567):1\u201312.","journal-title":"Nat Commun"},{"key":"1465_CR15","doi-asserted-by":"publisher","first-page":"16984","DOI":"10.1021\/acsnano.0c06190","volume":"46","author":"D Wei","year":"2020","unstructured":"Wei D, Yu Y, Zhang X, Wang Y, Chen H, Zhao Y, Wang F, Rong G, Wang W, Kang X, et al. Breaking the intracellular redox balance with diselenium nanoparticles for maximizing chemotherapy efficacy on patient-derived xenograft models. ACS Nano. 2020;46:16984\u201396.","journal-title":"ACS Nano"},{"issue":"2100599","key":"1465_CR16","first-page":"1","volume":"33","author":"L Wang","year":"2021","unstructured":"Wang L, Yu Y, Wei D, Zhang L, Zhang X, Zhang G, Ding D, Xiao H, Zhang D. A systematic strategy of combinational blow for overcoming cascade drug resistance via NIR-light-triggered hyperthermia. Adv Mater. 2021;33(2100599):1\u201310.","journal-title":"Adv Mater"},{"key":"1465_CR17","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1039\/C8CC02791A","volume":"54","author":"Q Chen","year":"2018","unstructured":"Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X, Yu Z. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance. Chem Commun. 2018;54:5369\u201372.","journal-title":"Chem Commun"},{"key":"1465_CR18","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1021\/acsnano.1c00076","volume":"15","author":"D Wei","year":"2021","unstructured":"Wei D, Yu Y, Huang Y, Jiang Y, Zhao Y, Nie Z, Wang F, Ma W, Yu Z, Huang Y, et al. A near-infrared-II polymer with tandem fluorophores demonstrates superior biodegradability for simultaneous drug tracking and treatment efficacy feedback. ACS Nano. 2021;15:5428\u201338.","journal-title":"ACS Nano"},{"issue":"15","key":"1465_CR19","first-page":"168","volume":"17","author":"M Bersanelli","year":"2016","unstructured":"Bersanelli M, Mosca E, Remondini D, Giampieri E, Sala C, Castellani G, Milanesi L. Methods for the integration of multi-omics data: mathematical aspects. BMC Bioinform. 2016;17(15):168\u201377.","journal-title":"BMC Bioinform"},{"issue":"524","key":"1465_CR20","first-page":"1","volume":"11","author":"Z Yin","year":"2020","unstructured":"Yin Z, Yan X, Wang Q, Deng Z, Tang K, Cao Z, Qiu T. Detecting prognosis risk biomarkers for colon cancer through multi-omics-based prognostic analysis and target regulation simulation modeling. Front Genet. 2020;11(524):1\u201316.","journal-title":"Front Genet"},{"issue":"4781","key":"1465_CR21","first-page":"1","volume":"20","author":"M Olivier","year":"2019","unstructured":"Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The need for multi-omics biomarker signatures in precision medicine. Int J Mol Sci. 2019;20(4781):1\u201313.","journal-title":"Int J Mol Sci"},{"key":"1465_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.adgen.2015.11.004","volume":"93","author":"YV Sun","year":"2016","unstructured":"Sun YV, Hu YJ. Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases. Adv Genet. 2016;93:147\u201390.","journal-title":"Adv Genet"},{"key":"1465_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.tibtech.2016.04.004","volume":"34","author":"C Bock","year":"2016","unstructured":"Bock C, Farlik M, Sheffield NC. Multi-omics of single cells: strategies and applications. Trends Biotechnol. 2016;34:605\u20138.","journal-title":"Trends Biotechnol"},{"issue":"eabc5267","key":"1465_CR24","first-page":"1","volume":"7","author":"J Chen","year":"2021","unstructured":"Chen J, Wang X, Yuan Y, Chen H, Zhang L, Xiao H, Chen J, Zhao Y, Chang J, Guo W, Liang XJ. Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine. Sci Adv. 2021;7(eabc5267):1\u201312.","journal-title":"Sci Adv"},{"key":"1465_CR25","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116:3436\u201386.","journal-title":"Chem Rev"},{"key":"1465_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","volume":"157","author":"B Elsadek","year":"2012","unstructured":"Elsadek B, Kratz F. Impact of albumin on drug delivery\u2013new applications on the horizon. J Control Release. 2012;157:4\u201328.","journal-title":"J Control Release"},{"key":"1465_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170:365\u201372.","journal-title":"J Control Release"},{"key":"1465_CR28","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1021\/acs.molpharmaceut.9b01221","volume":"17","author":"H Yuan","year":"2020","unstructured":"Yuan H, Guo H, Luan X, He M, Li F, Burnett J, Truchan N, Sun D. Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer. Mol Pharm. 2020;17:2275\u201386.","journal-title":"Mol Pharm"},{"key":"1465_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"1465_CR30","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41551-021-00728-7","volume":"5","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jiang Y, Wei D, Singh P, Yu Y, Lee T, Zhang L, Mandl HK, Piotrowski-Daspit AS, Chen X, et al. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nat Biomed Eng. 2021;5:1048\u201358.","journal-title":"Nat Biomed Eng"},{"key":"1465_CR31","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383.","journal-title":"Oncogene"},{"key":"1465_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-18-0083","volume":"9","author":"J Zhang","year":"2019","unstructured":"Zhang J, Lee YR, Dang F, Gan W, Menon AV, Katon JM, Hsu CH, Asara JM, Tibarewal P, Leslie NR, et al. PTEN methylation by NSD2 controls cellular sensitivity to DNA damage. Cancer Discov. 2019;9:1306\u201323.","journal-title":"Cancer Discov"},{"key":"1465_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1124\/jpet.108.139162","volume":"327","author":"M Jiang","year":"2008","unstructured":"Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther. 2008;327:300\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"1465_CR34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/sj.cdd.4402287","volume":"15","author":"C Yang","year":"2008","unstructured":"Yang C, Kaushal V, Haun RS, Seth R, Shah SV, Kaushal GP. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ. 2008;15:530\u201344.","journal-title":"Cell Death Differ"},{"issue":"101","key":"1465_CR35","first-page":"1","volume":"18","author":"J Lu","year":"2020","unstructured":"Lu J, Chen Z, Zhao H, Dong H, Zhu L, Zhang Y, Wang J, Zhu H, Cui Q, Qi C, et al. ABAT and ALDH6A1, regulated by transcription factor HNF4A, suppress tumorigenic capability in clear cell renal cell carcinoma. J Transl Med. 2020;18(101):1\u201315.","journal-title":"J Transl Med"},{"key":"1465_CR36","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3892\/ijo.2016.3469","volume":"48","author":"Y Guo","year":"2016","unstructured":"Guo Y, Lin D, Zhang M, Zhang X, Li Y, Yang R, Lu Y, Jin X, Yang M, Wang M, et al. CLDN6-induced apoptosis via regulating ASK1-p38\/JNK signaling in breast cancer MCF-7 cells. Int J Oncol. 2016;48:2435\u201344.","journal-title":"Int J Oncol"},{"issue":"1697","key":"1465_CR37","first-page":"1","volume":"9","author":"J Yin","year":"2018","unstructured":"Yin J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol. 2018;9(1697):1\u20138.","journal-title":"Front Immunol"},{"issue":"223","key":"1465_CR38","first-page":"1","volume":"2","author":"J Kang","year":"2019","unstructured":"Kang J, Lim L, Song J. ATP binds and inhibits the neurodegeneration-associated fibrillization of the FUS RRM domain. Commun Biol. 2019;2(223):1\u201310.","journal-title":"Commun Biol"},{"key":"1465_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.yexcr.2014.06.017","volume":"328","author":"G Rauner","year":"2014","unstructured":"Rauner G, Barash I. Xanthosine administration does not affect the proportion of epithelial stem cells in bovine mammary tissue, but has a latent negative effect on cell proliferation. Exp Cell Res. 2014;328:186\u201396.","journal-title":"Exp Cell Res"},{"key":"1465_CR40","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bbrc.2016.11.119","volume":"482","author":"YJ Kim","year":"2017","unstructured":"Kim YJ, Ryu HM, Choi JY, Cho JH, Kim CD, Park SH, Kim YL. Hypoxanthine causes endothelial dysfunction through oxidative stress-induced apoptosis. Biochem Biophys Res Commun. 2017;482:821\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1465_CR41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopha.2018.02.109","volume":"102","author":"M Jahani","year":"2018","unstructured":"Jahani M, Noroznezhad F, Mansouri K. Arginine: challenges and opportunities of this two-faced molecule in cancer therapy. Biomed Pharmacother. 2018;102:594\u2013601.","journal-title":"Biomed Pharmacother"},{"key":"1465_CR42","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s11064-017-2288-7","volume":"42","author":"GC Ferreira","year":"2017","unstructured":"Ferreira GC, McKenna MC. L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem Res. 2017;42:1661\u201375.","journal-title":"Neurochem Res"},{"issue":"101459","key":"1465_CR43","first-page":"1","volume":"44","author":"W Wang","year":"2022","unstructured":"Wang W, Cai J, Wen J, Li X, Yu Y, Zhang L, Han Q, Wei Z, Ma Y, Ying F, et al. Boosting ferroptosis via abplatin(iv) for treatment of platinum-resistant recurrent ovarian cancer. Nano Today. 2022;44(101459):1\u201313.","journal-title":"Nano Today"},{"issue":"e202201486","key":"1465_CR44","first-page":"1","volume":"61","author":"D Wei","year":"2022","unstructured":"Wei D, Huang Y, Wang B, Ma L, Karges J, Xiao H. Photo-reduction with NIR light of nucleus-targeting Pt(IV) nanoparticles for combined tumor-targeted chemotherapy and photodynamic immunotherapy. Angew Chem Int Ed Engl. 2022;61(e202201486):1\u20139.","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01465-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T12:10:45Z","timestamp":1654258245000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01465-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01465-y","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We provide ethics approval and consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We provide consent to publish that article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}